Serina Therapeutics (SER) Gross Margin (2018 - 2023)

Serina Therapeutics has disclosed Gross Margin across 6 years of filings, most recently posting 1.78% for Q4 2023.

• In Q4 2023, Gross Margin fell 8572.0% year-over-year to 1.78%; the TTM figure through Dec 2023 stood at 3.24% (down 5853.0% YoY), while the FY2023 annual figure was 3.24%, down 5853.0% from the prior year.
• Gross Margin came in at 1.78% for Q4 2023 at Serina Therapeutics, down from 117.24% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 117.24% in Q3 2023 to a low of 1.78% in Q4 2023.
• Average Gross Margin over 5 years is 75.12%, with a median of 85.61% recorded in 2019.
• The largest YoY upside for Gross Margin was 7280 bps in 2023 against a maximum downside of 8572 bps in 2023.
• Over 5 years, Gross Margin stood at 85.61% in 2019, then increased by 13 bps to 96.84% in 2020, then slipped by 5 bps to 91.67% in 2021, then fell by 5 bps to 87.5% in 2022, then plunged by 98 bps to 1.78% in 2023.
• Per Business Quant data, the three most recent Gross Margin figures were 1.78% in Q4 2023, 117.24% in Q3 2023, and 57.14% in Q2 2023.